RA in 2011: Advances in diagnosis, treatment and definition of remission

Nature Reviews Rheumatology

Volumn 8, Issue 2, 2012, Pages 65-66

  Burmester, Gerd R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; FOSTAMATINIB; PLACEBO; TOFACITINIB;

ANEMIA; CD40 GENE; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNE SYSTEM; IMMUNOASSAY; LABORATORY TEST; PRIORITY JOURNAL; PTPN22 GENE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STAT4 GENE; URINARY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; REMISSION INDUCTION; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 84856593136     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.201     Document Type: Review

References (10)

1. Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 69, 1580-1588 (2010).
2. Padyukov, L. et al. Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study group. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann. Rheum. Dis. 70, 259-265 (2011).
3. Stahl, E. A. et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 42, 508-514 (2010).
4. Chatzidionysiou, K. et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann. Rheum. Dis. 70, 1575-1580 (2011).
5. Fleischmann, R. et al. Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs. Arthritis Rheum. http://dx.doi.org/10.1002/art.33383.
6. Weinblatt, M. E. et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363, 1303-1312 (2010).
7. Smolen, J. S. et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631-637 (2010).
8. Felson, D. T. et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann. Rheum. Dis. 70, 404-413 (2011).
9. Shahouri, S. H. et al. Remission of rheumatoid arthritis in clinical practice. Application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum. 63, 3204-3215 (2011).
10. Klarenbeek, N. B. et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann. Rheum. Dis. 70, 1815-1821 (2011).